Skip to main content

Table 3 Weighted PFS values for the three clusters (groups)*

From: Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas

Groups

Trial No.

N

PFS6

PFS9

PFS12

A

1–5

106

15%

11%

9%

B

6–12

346

37%

25%

21%

C

13–16

77

41%

38%

33%

B+C

6–16

423

38%

27%

23%

  1. * Groups are shown in Figure 1, and the values were calculated from data in trials summarized in Table 1.
  2. PFS for groups B+C are weighted means of averages shown for groups B and C.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us